Resumen
Cardiac myofibroblast (CMF) are non-muscle cardiac cells that play a crucial role in wound healing and in pathological remodeling. These cells are mainly derived of cardiac fibroblast (CF) differentiation mediated by TGF-β1. Evidence suggests that bradykinin (BK) regulates cardiac fibroblast function in the heart. Both B1 and B2 kinin receptors (B1R and B2R, respectively) mediate the biological effects of kinins. We recently showed that both receptors are expressed in CMF and its stimulation decreases collagen secretion. Whether TGF-β1 regulates B1R and B2R expression, and how these receptors control antifibrotic activity in CMF remains poorly understood. In this work, we sought to study, the regulation of B1R expression in cultured CMF mediated by TGF-β1, and the molecular mechanisms involved in B1R activation on CMF intracellular collagen type-I levels. Cardiac fibroblast-primary culture was obtained from neonatal rats. Hearts were digested and CFs were attached to dishes and separated from cardiomyoctes. CMF were obtained from CF differentiation with TGF-β1 5 ng/mL. CF and CMF were treated with B1R and B2R agonists and with TGF-β1 at different times and concentrations, in the presence or absence of chemical inhibitors, to evaluate signaling pathways involved in B1R expression, collagen type-I and prostacyclin levels. B1R and collagen type-I levels were evaluated by western blot. Prostacyclin levels were quantified by an ELISA kit. TGF-β1 increased B1R expression via TGFβ type I receptor kinase (ALK5) activation and its subsequent signaling pathways involving Smad2, p38, JNK and ERK1/2 activation. Moreover, in CMF, the activation of B1R and B2R by their respective agonists, reduced collagen synthesis. This effect was mediated by the canonical signaling pathway; phospholipase C (PLC), protein kinase C (PKC), phospholipase A2 (PLA2), COX-2 activation and PGI2 secretion and its autocrine effect. TGF-β1 through ALK5, Smad2, p38, JNK and ERK1/2 increases B1R expression; whereas in CMF, B1R and B2R activation share common signaling pathways for reducing collagen synthesis.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 5197-5207 |
Número de páginas | 11 |
Publicación | Molecular Biology Reports |
Volumen | 46 |
N.º | 5 |
DOI | |
Estado | Published - oct. 1 2019 |
Financiación
This work was supported by Pharmacology Ph.D. Grant from CONICYT: 21080246 (MC); CONICYT Grant, Chile (FONDECYT 1130300 and 1170425 to G.D.A and FONDAP 15130011 to S.L. and G.D.A). This work was supported by Pharmacology Ph.D. Grant from CONICYT: 21080246 (MC); CONICYT Grant, Chile (FONDECYT 1130300 and 1170425 to G.D.A and FONDAP 15130011 to S.L. and G.D.A).
Financiadores | Número del financiador |
---|---|
Pharmacology Ph.D. | |
Comisión Nacional de Investigación Científica y Tecnológica | |
Fondo Nacional de Desarrollo Científico y Tecnológico | 1130300, 1170425, FONDAP 15130011 |
ASJC Scopus Subject Areas
- Molecular Biology
- Genetics